查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012375

溫血灌注系統市場：按類型、技術和最終用戶分類－2026-2032年全球預測

Warm Blood Perfusion System Market by Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，溫血灌注系統市場價值將達到 8,175 萬美元，到 2026 年將成長至 9,021 萬美元，到 2032 年將達到 1.6854 億美元，複合年成長率為 10.88%。

主要市場統計數據
基準年 2025 8175萬美元
預計年份：2026年 9021萬美元
預測年份 2032 1.6854億美元
複合年成長率 (%) 10.88%

對重塑溫血灌注系統引入和研究的臨床、技術促進因素和相關人員趨勢進行關鍵概述。

溫血灌注系統的演進使其從小眾實驗工具轉變為具有重要臨床意義的平台，對器官保存、外科手術流程和轉化研究產生深遠影響。本文概述了推動投資的臨床需求、促進更廣泛應用的技術進步，以及影響需求和應用路徑的相關人員（外科醫生、灌注技師、器官捐贈團隊和科研人員）。

近期臨床、監管和技術方面的變化如何迅速改變器官保存實踐和灌注系統的商業策略。

近年來，臨床需求、監管關注以及醫療設備的快速發展共同推動了器官保存領域的變革。灌注技術的進步超越了傳統的冷凍保存模式，對器官活力評估、即時監測和延長保存期提出了新的要求。這些變革不僅體現在技術層面，也體現在結構層面，影響供應鏈、培訓課程以及移植醫學領域的「卓越中心」模式。

探討近期美國關稅變化對供應鏈、採購決策和製造計畫的多方面營運和策略影響。

美國將於2025年實施的新關稅政策，為溫血灌注系統的供應商、醫療保健採購商和研究機構帶來了複雜的商業環境。關稅變化影響了供應商的成本結構、採購計劃以及生產和組裝位置的選址決策。為此，製造商正在重新評估其供應鏈的韌性，並探索替代籌資策略，以降低新增關稅的風險。

詳細的細分分析揭示了類型、技術和最終用戶的差異如何導致不同的臨床方案、採購選擇和產品開發重點。

關鍵的細分洞察揭示了臨床應用案例、採購選擇和最終用戶需求如何因設備類型、技術設計和醫療環境而異。就設備類型而言，低溫療法和常溫療法的差異會影響基於臨床方案、監測需求和器官類型的候選設備選擇。低溫療法往往著重於冷灌注支持設備，而常溫療法則優先考慮維持生理體溫和積極的代謝支持。

從區域比較觀點看美洲、歐洲、中東和非洲以及亞太市場的臨床引入、監管複雜性和商業化路徑。

區域分析揭示了各主要地區在器官移植應用趨勢、監管預期和醫療基礎設施方面的差異，從而塑造了不同的商業化和臨床應用路徑。在美洲，成熟的移植網路和集中的研究中心促進了試驗計畫和早期臨床應用，但公立和私立醫療系統之間的器官捐贈週期和報銷結構可能存在顯著差異。在此背景下，產生符合支付方優先事項和臨床工作流程實際情況的證據至關重要。

策略性企業措施和夥伴關係模式，旨在實現產品差異化、加速證據生成，並將商業性獎勵與臨床結果結合。

對主要企業的洞察主要集中在主要企業新興企業如何透過產品差異化、服務模式和策略夥伴關係來確立自身市場定位。市場參與企業正投資於以使用者為中心的設計功能，例如簡化的介面、標準化的連接器和整合的監測系統，以減輕培訓負擔並提高治療的一致性。除了硬體開發之外，企業還擴大提供數據平台，以實現灌注參數的時間序列追蹤，並將治療過程中的指標與臨床結果關聯起來。

為製造商和醫療保健系統領導者提供切實可行的策略步驟，以展示臨床價值、增強供應韌性，並透過夥伴關係和卓越的服務加速部署。

針對產業領導者的實際建議強調採取切實可行的步驟，以加速臨床應用、強化價值鏈，並向支付者和醫療服務提供者證明其價值。首先，投資嚴格的臨床檢驗和真實世界證據 (RWE) 項目，以衡量以患者為中心的療效和營運效益。可靠的證據是醫保報銷討論的基礎，並為臨床醫生提供所需的對比數據，以便他們能夠自信地採用新的工作流程。

對用於確保所提出研究結果的透明度、可重複性和相關性的證據收集、相關人員和分析過程進行清晰的解釋。

本執行摘要的調查方法結合了定性和定量證據收集，旨在確保研究結果的透明度、可重複性和相關性，以滿足臨床和商業相關人員的需求。主要研究包括對臨床醫生、灌注專家、採購負責人和生物醫學工程師進行結構化訪談，並輔以在臨床和實驗室環境中進行的觀察性研究。透過這些努力，我們了解了整個醫療保健環境中的工作流程限制、培訓需求和設備性能的考量。

結論強調了證據生成、以臨床醫生為中心的設計以及強力的商業化策略如何決定實施的成功以及對患者的影響。

總之，溫血灌注系統正處於一個轉折點，臨床潛力、技術成熟度和商業策略在此交匯融合，有望重塑器官保存實務。持續進步取決於產生可靠的臨床證據、設計能夠適應不同醫療環境的設備，以及建立能夠抵禦政策和貿易衝擊的彈性供應鏈。優先考慮數據驅動檢驗、以臨床醫生為中心的設計以及卓越服務的利益相關人員，將更有能力把創新轉化為日常臨床效益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：溫血灌流系統市場：依類型分類

  • 低溫
  • 室溫

第9章：溫血灌流系統市場：依技術分類

  • 免洗墨水匣
  • 可重複使用系統

第10章：溫血灌流系統市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 移植中心

第11章 溫血灌流系統市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 溫血灌流系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 溫血灌流系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國：溫血灌流系統市場

第15章 中國：溫血灌注系統市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Asahi Kasei Medical Co Ltd
  • Bridge to Life Ltd
  • EBERS Medical Technology SL
  • Fresenius SE & Co KGaA
  • Getinge AB
  • Harvard Bioscience Inc
  • LivaNova PLC
  • Medtronic PLC
  • Merck KGaA
  • Nipro Corporation
  • Organ Assist BV
  • Organ Recovery Systems Inc
  • OrganOx Limited
  • Paragonix Technologies Inc
  • Preservation Solutions Inc
  • Repligen Corporation
  • Sartorius AG
  • Shenzhen Lifotronic Technology Co Ltd
  • Spectrum Medical
  • Terumo Corporation
  • TransMedics Inc
  • Water Medical System LLC
  • XVIVO Perfusion AB
Product Code: MRR-431C35F6C243

The Warm Blood Perfusion System Market was valued at USD 81.75 million in 2025 and is projected to grow to USD 90.21 million in 2026, with a CAGR of 10.88%, reaching USD 168.54 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 81.75 million
Estimated Year [2026] USD 90.21 million
Forecast Year [2032] USD 168.54 million
CAGR (%) 10.88%

A focused introduction to the clinical drivers, technological enablers, and stakeholder dynamics that are reshaping adoption and research for warm blood perfusion systems

The evolution of warm blood perfusion systems has shifted from a niche experimental tool to a clinically significant platform influencing organ preservation, surgical workflows, and translational research. This introduction frames the clinical imperatives that drive investment, the technological advances that enable broader adoption, and the stakeholder ecosystem-surgeons, perfusionists, procurement teams, and research scientists-that shapes demand and implementation pathways.

Across healthcare settings, interest in systems that better preserve organ viability and expand the donor pool has intersected with innovation in portable devices, biocompatible materials, and user-centered design. Consequently, early adopters have focused on operational integration, training, and outcomes monitoring. These practical concerns coexist with ongoing efforts to standardize protocols and measure comparative effectiveness across differing approaches to organ perfusion.

Looking ahead, multi-disciplinary collaboration will determine how systems are validated in routine care and research. Clinical trial designs, real-world evidence collection, and economic evaluations will inform clinician confidence and payer engagement. Therefore, stakeholders should prioritize interoperability, ease of use, and demonstrable improvements in post-transplant outcomes as the core measures of value when considering deployment.

How recent clinical, regulatory, and technological inflection points are rapidly transforming organ preservation practice and commercial strategies for perfusion systems

Recent years have seen transformative shifts in the landscape of organ preservation driven by converging clinical needs, regulatory attention, and rapid device innovation. Advances in perfusion technology have expanded beyond cold storage paradigms and established new expectations for organ viability assessment, real-time monitoring, and extended preservation windows. These shifts are not only technical but also structural, affecting supply chains, training curricula, and center-of-excellence models for transplant care.

Simultaneously, the regulatory environment has become more engaged with device-specific evidence requirements and post-market surveillance, prompting manufacturers to design studies that demonstrate both safety and clinically meaningful benefits. In parallel, payer interest in outcomes-oriented reimbursement has elevated the importance of cost-consequence analyses and demonstrable reductions in complications or re-transplantation rates.

Clinically, the integration of monitoring technologies, biomarkers, and decision-support tools has moved organ perfusion from a procedural adjunct to a data-driven intervention. This trajectory encourages partnerships between device makers and research institutions, fostering iterative development cycles grounded in translational science. As a result, healthcare organizations are re-evaluating procurement criteria to emphasize long-term clinical value and system-level compatibility rather than initial acquisition price alone.

Exploring the multifaceted operational and strategic repercussions of recent United States tariff changes on supply chains, procurement decisions, and manufacturing plans

The introduction of new tariff policies in the United States during 2025 has created a complex operating environment for suppliers, healthcare purchasers, and research institutions engaged with warm blood perfusion systems. Tariff changes influence supplier cost structures, procurement timelines, and decisions about where to locate manufacturing and assembly operations. In response, manufacturers are reassessing supply chain resilience and considering alternative sourcing strategies to mitigate exposure to incremental duties.

Procurement teams at hospitals and transplant centers are navigating price volatility and longer lead times, which can affect budgeting cycles and capital planning. To maintain continuity of care and research capacity, many organizations are exploring contractual approaches that include contingency sourcing, inventory buffers, and tighter collaboration with vendors on demand forecasting. Such measures aim to reduce the operational impacts of tariff-driven cost pressures while preserving access to critical technologies.

From an industry perspective, these trade policy shifts are accelerating conversations about regional production footprints, the trade-offs between reusable and disposable components, and potential value-based procurement agreements that link payment to clinical outcomes. Consequently, strategic responses include manufacturing localization, deeper supplier qualification processes, and a renewed emphasis on designing devices with modularity and supply chain transparency in mind.

In-depth segmentation analysis revealing how type, technology, and end-user distinctions drive divergent clinical protocols, procurement choices, and product development priorities

Key segmentation insights reveal how clinical use cases, procurement choices, and end-user needs vary according to device type, technology design, and care setting. When considering Type, distinctions between Hypothermic and Normothermic approaches shape clinical protocols, monitoring requirements, and candidate selection for different organ types. Hypothermic strategies tend to emphasize cold perfusion adjuncts, whereas Normothermic approaches prioritize physiological temperature maintenance and active metabolic support.

When considering Technology, the choice between Disposable Cartridge designs and Reusable System architectures impacts cost profiles, sterilization workflows, and device lifecycle planning. Disposable cartridges can simplify logistics and reduce cross-contamination risk, while reusable systems demand robust maintenance programs and capital investment decisions tied to throughput and utilization rates. These trade-offs also influence training needs and the configuration of service-level agreements.

When considering End User, distinct priorities emerge across Hospitals, Research Institutes, and Transplant Centers, each of which values different combinations of reliability, data granularity, and ease of integration. Hospitals often focus on operational efficiency and clinician workflow, research institutes prioritize experimental flexibility and data capture for studies, and transplant centers require validated clinical performance and compatibility with surgical routines. Integrating these segmentation lenses enables stakeholders to align product design, commercialization strategies, and support services with the real-world needs of diverse customers.

Comparative regional perspective on clinical adoption, regulatory complexity, and commercialization pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional insights demonstrate how adoption dynamics, regulatory expectations, and healthcare infrastructure vary across major geographies, shaping different pathways to commercialization and clinical uptake. In the Americas, established transplant networks and concentrated research centers facilitate pilot programs and early clinical adoption, but procurement cycles and reimbursement structures can vary sharply between public and private systems. This environment rewards evidence generation that aligns with payer priorities and clinical workflow realities.

In Europe, Middle East & Africa, diverse regulatory regimes and heterogeneous healthcare financing models create both challenges and opportunities for manufacturers. Countries with centralized procurement mechanisms may offer scale but require rigorous conformity with regional medical device regulations and harmonized clinical evidence. Conversely, certain markets within the region can serve as innovation testbeds where academic centers collaborate closely with industry partners to refine technologies.

In the Asia-Pacific region, the rapid expansion of healthcare infrastructure, growing transplant volumes, and strategic investments in medical technology create fertile conditions for adoption. However, market entry strategies must adapt to varied regulatory pathways and differing clinician preferences. Across all regions, success depends on tailored real-world evidence, responsive training programs, and supply chain arrangements that reflect local logistics and service expectations.

Strategic company plays and partnership models that differentiate product offerings, accelerate evidence generation, and align commercial incentives with clinical outcomes

Key companies insights focus on how leading and emerging organizations are positioning themselves through product differentiation, service models, and strategic partnerships. Market participants are investing in user-centric design features such as simplified interfaces, standardized connectors, and integrated monitoring to reduce training burdens and improve procedural consistency. Complementing hardware development, firms are increasingly offering data platforms that enable longitudinal tracking of perfusion parameters and correlate intra-procedural metrics with clinical outcomes.

Strategic collaborations between device manufacturers and academic centers are accelerating evidence generation and iterative product refinement. These partnerships enable manufacturers to validate protocols across a range of donor and recipient profiles while providing clinical partners with access to cutting-edge technology. Competitive advantage is often derived from the depth of clinical relationships, responsiveness of customer support, and the ability to bundle devices with consumables and training services that reduce implementation friction.

Additionally, companies are evaluating service-led models that align incentives with clinical outcomes, including extended warranties, training packages, and outcome-focused support agreements. Such approaches can facilitate adoption among risk-averse institutions by shifting some performance risk to the supplier while fostering long-term partnerships based on shared goals for patient outcomes and operational efficiency.

Practical strategic steps for manufacturers and health system leaders to validate clinical value, strengthen supply resiliency, and accelerate adoption through partnerships and service excellence

Actionable recommendations for industry leaders emphasize pragmatic steps to accelerate clinical adoption, strengthen supply chains, and demonstrate value to payers and providers. First, invest in rigorous clinical validation and real-world evidence programs that measure patient-centered outcomes and operational benefits. Robust evidence will underpin reimbursement discussions and provide clinicians with the comparative data needed to adopt new workflows with confidence.

Second, optimize product portfolios by balancing modular reusable systems with thoughtfully designed disposable cartridges to match customer preferences and institutional capabilities. This approach supports flexible procurement strategies while addressing sterilization and throughput considerations. Third, enhance post-sale engagement through comprehensive training, data-driven support, and rapid-response service networks to minimize downtime and maximize device utilization.

Fourth, pursue strategic manufacturing and sourcing decisions to reduce tariff exposure and improve supply chain resilience, including nearshoring critical components or establishing dual-source arrangements. Finally, deepen collaborations with transplant centers and research institutes to co-develop protocols, share outcomes data, and refine device features. These partnerships can accelerate iteration cycles and translate clinical insights into product improvements, ultimately supporting broader uptake and sustained value delivery.

Clear description of evidence collection, stakeholder engagement, and analytical processes used to ensure transparency, reproducibility, and relevance of the insights presented

The research methodology underpinning this executive summary combined qualitative and quantitative evidence collection designed to ensure transparency, reproducibility, and relevance to clinical and commercial stakeholders. Primary research included structured interviews with clinicians, perfusion specialists, procurement officers, and biomedical engineers, supplemented by observational studies in clinical and laboratory settings. These engagements were used to capture workflow constraints, training needs, and device performance considerations across care settings.

Secondary research involved a systematic review of peer-reviewed literature, clinical trial registries, regulatory filings, and technical white papers to synthesize the state of evidence around perfusion modalities, device safety, and outcome measures. Comparative analyses of device features, sterilization protocols, and consumable lifecycle impacts were conducted to understand trade-offs between disposable and reusable approaches.

Triangulation of findings across primary and secondary sources helped validate key themes and identify gaps in evidence that warrant further investigation. Throughout the process, attention was given to documenting assumptions, data provenance, and methodological limitations so that readers can assess the applicability of insights to their unique operational contexts.

Concluding synthesis highlighting how evidence generation, clinician-centered design, and resilient commercialization strategies will determine successful adoption and patient impact

In conclusion, warm blood perfusion systems are at an inflection point where clinical promise, technological maturity, and commercial strategies are converging to reshape organ preservation practices. Sustained progress will depend on generating robust clinical evidence, designing devices that align with heterogeneous care settings, and building resilient supply chains that can absorb policy and trade-related shocks. Stakeholders who prioritize data-driven validation, clinician-centered design, and service excellence will be best positioned to translate innovation into routine clinical benefit.

Moreover, cross-sector collaboration between manufacturers, transplant centers, and research institutions will accelerate both technical refinement and the establishment of standardized protocols. As the ecosystem evolves, value will accrue to organizations that can demonstrate measurable patient outcomes, streamline operational integration, and offer compelling total-cost-of-care narratives to payers and health systems. Ultimately, the pathway to broader adoption lies in coupling scientific rigor with practical implementation strategies that reduce barriers to clinical use and ensure reproducible benefits for patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Warm Blood Perfusion System Market, by Type

  • 8.1. Hypothermic
  • 8.2. Normothermic

9. Warm Blood Perfusion System Market, by Technology

  • 9.1. Disposable Cartridge
  • 9.2. Reusable System

10. Warm Blood Perfusion System Market, by End User

  • 10.1. Hospitals
  • 10.2. Research Institutes
  • 10.3. Transplant Centers

11. Warm Blood Perfusion System Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Warm Blood Perfusion System Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Warm Blood Perfusion System Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Warm Blood Perfusion System Market

15. China Warm Blood Perfusion System Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Asahi Kasei Medical Co Ltd
  • 16.6. Bridge to Life Ltd
  • 16.7. EBERS Medical Technology SL
  • 16.8. Fresenius SE & Co KGaA
  • 16.9. Getinge AB
  • 16.10. Harvard Bioscience Inc
  • 16.11. LivaNova PLC
  • 16.12. Medtronic PLC
  • 16.13. Merck KGaA
  • 16.14. Nipro Corporation
  • 16.15. Organ Assist BV
  • 16.16. Organ Recovery Systems Inc
  • 16.17. OrganOx Limited
  • 16.18. Paragonix Technologies Inc
  • 16.19. Preservation Solutions Inc
  • 16.20. Repligen Corporation
  • 16.21. Sartorius AG
  • 16.22. Shenzhen Lifotronic Technology Co Ltd
  • 16.23. Spectrum Medical
  • 16.24. Terumo Corporation
  • 16.25. TransMedics Inc
  • 16.26. Water Medical System LLC
  • 16.27. XVIVO Perfusion AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES WARM BLOOD PERFUSION SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY HYPOTHERMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY HYPOTHERMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY HYPOTHERMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY NORMOTHERMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY NORMOTHERMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY NORMOTHERMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY DISPOSABLE CARTRIDGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY DISPOSABLE CARTRIDGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY DISPOSABLE CARTRIDGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY REUSABLE SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY REUSABLE SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY REUSABLE SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. AMERICAS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 28. AMERICAS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. AMERICAS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. AMERICAS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. NORTH AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. NORTH AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. NORTH AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. NORTH AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 35. LATIN AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. LATIN AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. LATIN AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 38. LATIN AMERICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. EUROPE, MIDDLE EAST & AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. EUROPE, MIDDLE EAST & AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. EUROPE, MIDDLE EAST & AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 42. EUROPE, MIDDLE EAST & AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. EUROPE WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. EUROPE WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. EUROPE WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. EUROPE WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. MIDDLE EAST WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. MIDDLE EAST WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. MIDDLE EAST WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 50. MIDDLE EAST WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. AFRICA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. ASEAN WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. ASEAN WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. ASEAN WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. ASEAN WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GCC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GCC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GCC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 67. GCC WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPEAN UNION WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPEAN UNION WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPEAN UNION WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPEAN UNION WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. BRICS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. BRICS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. BRICS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. BRICS WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. G7 WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. G7 WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. G7 WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. G7 WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NATO WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NATO WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NATO WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. NATO WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. UNITED STATES WARM BLOOD PERFUSION SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. UNITED STATES WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. UNITED STATES WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. UNITED STATES WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. CHINA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. CHINA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. CHINA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. CHINA WARM BLOOD PERFUSION SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)